Cannabis brownies tested on seniors in tiny study
NCT ID NCT06055309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looked at how cannabis affects mood, thinking, balance, and vital signs in older adults. Three participants who had used marijuana before without problems ate cannabis-infused brownies. Researchers measured blood pressure, balance, and cognitive function. Because it is very small, the results are just a first step and cannot be used to make broad conclusions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cannabis (baked into brownies)
- What this could lead to
- If successful, this could provide initial data on how cannabis affects older adults, guiding future research on safety and effects in this age group.
- What could go wrong
- This is a very small pilot study with only 3 participants, so results may not apply to the general older adult population. It is early-stage and exploratory.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
3 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-reported history of marijuana use with no serious adverse effects * Negative urine toxicology screen for psychoactive drugs (cocaine, fentanyl, methadone, opiates, buprenorphine, methamphetamine, amphetamines, barbiturates, oxycodone, benzodiazepines, phencyclidine, and THC) and CBD * Negative breath alcohol concentration * Report ≥1 year abstinence from nicotine and tobacco * Report ≥1 month of abstinence from THC- and CBD- containing products and be willing to abstain from these products for the study duration * Blood pressure (BP) reading ≤140/90 and ≥110/70 at the time of screening * Read and understand English (because assessments are validated in English) * Menopause as defined as no reported menstruation for ≥12 months (females only) * Negative urine pregnancy test (females only) * Stable medical conditions controlled by non-psychoactive medications that do not alter THC/CBD metabolism (e.g., hypertension under control with certain antihypertensives; type II diabetes controlled by metformin) Exclusion Criteria: * A history of moderate to severe substance use disorders (SUDs) (except tobacco), according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), and no recent history (≥1 year) of SUD * Current tobacco/nicotine use * ECG abnormalities at screening including but not limited to: bradycardia (\<55 beats per minute); prolonged QTc interval (\>450 msec); Wolff-Parkinson White syndrome; wide complex tachycardia; 2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle branch block; pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic) * Have a serious and uncontrolled medical condition (major cardiovascular, renal, endocrine, or hepatic disorder) including a history of serious head trauma or neurological disorder (e.g., seizure disorder) * Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for lifetime psychosis, schizophrenia, or bipolar disorder or current major depressive disorder, suicidality (e.g., last month suicidal ideation or suicide attempt in past year, as measured by Columbia Suicide Severity Rating Scale) or have significant psychiatric symptoms of another disorder * Diagnosis of a cognitive disorder (Alzheimer's Disease, dementia) or a score of \<25 on the Montreal Cognitive Assessment (MoCA) for Dementia during screening * Currently taking any prescribed medication for a psychiatric disorder * Current use of over-the-counter medication or prescription psychoactive drugs that would be expected to have major interaction with THC (e.g., warfarin, serotonin reuptake inhibitors, tricyclic antidepressants, sildenafil). * Reported cancer-related fibromyalgia or neuropathic pain conditions * Have a medical contraindication to, or prior serious adverse events from, cannabis or brownie ingredients (e.g., food sensitivities to gluten/wheat, chocolate, eggs) * Consume the equivalent of \>2 cups of coffee/day (to reduce variability related to metabolic interactions with caffeine) * Have any of the following: uncontrolled hypertension (i.e., systolic \>140 mm Hg and/or diastolic \>90 mm Hg on three separate occasions; systolic \>170 or diastolic \>110 on any occasion), liver function tests \>3 times normal, blood urea Nitrogen and Creatinine outside normal range * Have a physical limitation that will interfere with completing study tasks * Have child-bearing potential (women)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Health services for the aged are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arkansas for Medical Science
Little Rock, Arkansas, 72205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.